Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.

ABSTRACT:

Objectives

This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated.

Methods

In this prospective observational study, GI cancer patients and healthy individuals who had received 2 doses of inactivated COVID-19 vaccines were included. The data regarding adverse effects, serum anti-receptor binding domain (RBD)-IgG, neutralizing antibodies (NAbs), and frequencies of MBCs were collected prospectively.

Results

The inactivated COVID-19 vaccines were safe and well tolerated. Serum anti-RBG-IgG and NAbs were lower for cancer patients. Old age, high ASA score, and receiving active chemo

SUBMITTER: Li T 

PROVIDER: S-EPMC9316719 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature